Orion Corporation
P.O. Box 84
1111 Cedar Creek Road
Grafton
Wisconsin
53024
United States
Tel: 414-377-2210
91 articles with Orion Corporation
-
Darolutamide approved for additional prostate cancer indication in China
3/20/2023
The Chinese National Medical Products Administration has approved the oral androgen receptor inhibitor darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.
-
Darolutamide receives EU approval for additional indication in prostate cancer
3/1/2023
The European Commission has granted marketing authorisation in the European Union for darolutamide, an oral androgen receptor inhibitor, plus androgen deprivation therapy in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer.
-
Darolutamide receives approval for additional prostate cancer indication in Japan
2/27/2023
The Ministry of Health, Labor and Welfare in Japan has approved the oral androgen receptor inhibitor darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate cancer.
-
Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
1/27/2023
ORION CORPORATION announced Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer.
-
Amneal Announces Strategic European Partnership with Orion Corporation
1/4/2023
Amneal Pharmaceuticals, Inc. announced it has signed a long-term license agreement with Orion Corporation to commercialize a number of Amneal’s complex generic products.
-
Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand
1/4/2023
Orion Corporation announced it has signed a long-term license agreement with Amneal Pharmaceuticals, Inc. to commercialise Amneal’s generic products in Orion territories.
-
U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
8/8/2022
Orion’s collaboration partner Bayer announced the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral androgen receptor inhibitor darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.
-
Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer
7/13/2022
Merck, known as MSD outside the United States and Canada, and Orion Corporation announced a global development and commercialization agreement for Orion’s investigational candidate ODM-208 and other drugs targeting cytochrome P450 11A1, an enzyme important in steroid production.
-
Orion and MSD announce global collaboration for the development and commercialisation of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer
7/13/2022
Orion and MSD announce global collaboration for the development and commercialisation ofODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer
-
Orion Acquires Inovet’s Animal Health Business
6/15/2022
Orion Corporation has entered into an agreement with Belgian private company Inovet BV to acquire its wholly owned subsidiary V.M.D. NV and all companies belonging to V.M.D. NV’s group of companies.
-
Orion announced that it will be focusing on pain and oncology going forward. As a result, 32 working professionals within the company will be terminated, although six of those will be offered different positions.
-
Orion enters into exclusive agreement with Jemincare for novel non-opioid drug candidate for the treatment of pain
5/6/2022
Orion Corporation has entered into an agreement with Chinese Jemincare, through which Orion will receive exclusive global development and commersialisation rights, excluding the Greater China area, for a potent and selective NaV 1.8 blocker for the treatment of acute and chronic pain.
-
The FDA accepted Bayer's supplemental New Drug Application for its proposed oral treatment for metastatic hormone-sensitive prostate cancer.
-
Orion is planning to refocus its R&D – in the future focus would be on cancer and pain
3/24/2022
Orion is planning to change and refocus the strategy of its R&D function. The company would invest in the research and development of new proprietary drugs in two therapy areas, cancer and pain.
-
Orion Corporation announced its plans to shift focus to new proprietary drugs in oncology and pain, expecting to cut 37 jobs.
-
Bayer is heading back to the FDA to seek approval for a new indication of its prostate cancer drug Nubeqa, following positive Phase III results.
-
Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU
2/18/2022
Clinical phase I data on Orion Corporation’s ODM-208, a first-in-class oral, non-steroidal and selective inhibitor of CYP11A1, the first and rate-limiting enzyme of steroid biosynthesis, were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium.
-
Phase III Investigational Trial of NUBEQA® (darolutamide) in Combination with Docetaxel and Androgen Deprivation Therapy (ADT) Meets Primary Endpoint of Significantly Increasing Overall Survival (OS) in Patients with mHSPC
12/3/2021
The Phase III ARASENS trial investigating the use of the oral androgen receptor inhibitor NUBEQA® in metastatic hormone-sensitive prostate cancer has met its primary endpoint.
-
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
12/3/2021
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
-
Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation
8/18/2021
Alligator Bioscience announced that the company has entered into a research collaboration and license agreement with Orion Corporation, a global pharmaceutical company based in Finland, to discover and develop together new bispecific antibody cancer therapeutics